Advertisement
UK markets open in 2 hours 47 minutes
  • NIKKEI 225

    38,588.33
    +106.22 (+0.28%)
     
  • HANG SENG

    18,267.61
    +352.06 (+1.97%)
     
  • CRUDE OIL

    81.53
    -0.04 (-0.05%)
     
  • GOLD FUTURES

    2,342.70
    -4.20 (-0.18%)
     
  • DOW

    38,834.86
    +56.76 (+0.15%)
     
  • Bitcoin GBP

    51,585.34
    +32.68 (+0.06%)
     
  • CMC Crypto 200

    1,350.64
    -38.76 (-2.79%)
     
  • NASDAQ Composite

    17,862.23
    +5.21 (+0.03%)
     
  • UK FTSE All Share

    4,467.95
    +30.42 (+0.69%)
     

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

DBV Technologies S.A.
DBV Technologies S.A.

Montrouge, France, February 27, 2023

DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 2, at 5:00 p.m. ET to report full year 2022 financial results and provide a business update.

Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call:

  • United States: 1-866-777-2509

  • International: 1-412-317-5413

ADVERTISEMENT

A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Viaskin and EPIT are trademarks of DBV Technologies.

Attachment